Natera awarded 30% ongoing royalty for MRD-related patents

Natera (NTRA) provided an update on a recent decision issued by the U.S. District Court in the District of Delaware regarding Natera’s litigation with ArcherDx and Invitae. In a decision issued April 6, the Court ordered an ongoing royalty to Natera of 30% on post-injunction revenues from infringing MRD-related product sales that fall within the exceptions to the injunction, which was issued by the Court on November 21, 2023. The jury had awarded an effective royalty of 20.5% on pre-injunction revenues, which remains unchanged. With respect to the non-MRD products, the jury’s verdict of patent validity and direct infringement also remains intact. Natera has over 650 issued or pending patents.